Lexeo Therapeutics (LXEO) Change in Account Payables (2022 - 2026)
Lexeo Therapeutics recorded quarterly Change in Account Payables of -$1.6 million in Q1 2026, down 898.0% quarter-over-quarter from $200000.0 in Q4 2025, and down 131.03% year-over-year from $5.1 million in Q1 2025.
Lexeo Therapeutics' Change in Account Payables history runs 5 years deep, the most recent figure standing at -$1.6 million for Q1 2026.
- In Q1 2026, Change in Account Payables fell 131.03% year-over-year to -$1.6 million; the TTM figure through Mar 2026 stood at -$8.3 million (down 220.6% YoY), while the FY2025 annual figure was -$1.6 million, down 165.64% from the prior year.
- Change in Account Payables came in at -$1.6 million for Q1 2026 at Lexeo Therapeutics, down from $200000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $8.4 million in Q2 2025 to a low of -$15.3 million in Q3 2025.
- A 5-year average of -$155714.3 and a median of $342000.0 in 2023 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables jumped 838.62% in 2024 and plunged 660.91% in 2025, its largest moves.
- Lexeo Therapeutics' Change in Account Payables stood at -$1.2 million in 2022, then jumped by 132.27% to $394000.0 in 2023, then sank by 618.27% to -$2.0 million in 2024, then soared by 109.79% to $200000.0 in 2025, then plunged by 898.0% to -$1.6 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$1.6 million, $200000.0, and -$15.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | -1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.60 Mn |
| Mar 31, 2026 | -1.60 Mn |
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | -15.27 Mn |
| Sep 30, 2025 | -15.27 Mn |
| Jun 30, 2025 | 8.36 Mn |
| Jun 30, 2025 | 8.36 Mn |
| Mar 31, 2025 | 5.14 Mn |
| Mar 31, 2025 | 5.14 Mn |
| Dec 31, 2024 | -2.04 Mn |
| Dec 31, 2024 | -2.04 Mn |
| Sep 30, 2024 | 2.72 Mn |
| Sep 30, 2024 | 2.72 Mn |
| Jun 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | 1.06 Mn |
| Mar 31, 2024 | 639,000.00 |
| Mar 31, 2024 | 639,000.00 |
| Dec 31, 2023 | 394,000.00 |
| Dec 31, 2023 | 394,000.00 |
| Sep 30, 2023 | 290,000.00 |
| Sep 30, 2023 | 290,000.00 |
| Jun 30, 2023 | -1.91 Mn |
| Jun 30, 2023 | -1.91 Mn |
| Mar 31, 2023 | 1.04 Mn |
| Mar 31, 2023 | 1.04 Mn |
| Dec 31, 2022 | -1.22 Mn |
| Dec 31, 2022 | -1.22 Mn |